Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
rubber dildos.
Popular Articles

Accouncing The Leading European Congress On Cardiac Arrhythmias And Pacing: EUROPACE 2009
EUROPACE, the official congress of the European Heart Rhythm Association (EHRA), is the foremost European meeting on cardiac arrhythmias and pacing. More than 4,000 participants are expected to attend this year"s event, whose main themes are atrial fibrillation and sudden cardiac death.
diet pills
Passport Health Of Massachusetts Warns New Englanders, "Exploding Mosquito Population Can Be Deadly, Look For Repellents With At Least 30% DEET!"
Passport Health of Massachusetts, specialists in vaccinations against dread diseases faced by international travelers, is concerned that eastern New England"s wettest spring and early summer in decades can be more deadly than usual.
News of the day
Sleep Debt May Result From Watching Television Before Bedtime
According to a research abstract presented on June 8, at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies, television watching may be an important determinant of bedtime, and may contribute to chronic sleep debt.
Diagnostics

Stem Cell Therapeutics Receives Clearance From Health Canada To Proceed With The Phase IIb Clinical Stroke Trial

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS)("SCT" or "the Company") has received a No Objection Letter ("NOL") from Health Canada for the modified REGENESIS protocol using NTx®-265 for a Phase IIb clinical trial treating acute ischemic stroke. Dr. Alan Moore, President and CEO, commented as follows: "We are pleased that Health Canada has issued an NOL for the modified REGENESIS clinical trial. This welcome development means that we are able to proceed with recruitment of patients, testing the NTx®-265 regimen in patients with acute ischemic stroke in Canada again and demonstrating the ability of this novel approach to speed recovery from stroke disabilities. This satisfying development can be directly attributed to the perseverance and strong belief of all the SCT staff that NTx®-265 will, in the future, redefine the therapies available to patients recovering from acute ischemic stroke, traumatic brain injury, and neurological disease." About REGENESIS (a Phase II prospective, randomized, double-blind, placebo controlled study of NTx®-265: hCG and epoetin alfa in acute ischemic stroke patients): NTx®-265 is SCT"s lead therapeutic regimen of two approved and clinically well-defined drugs, human Chorionic Gonadotropin ("hCG") and Erythropoietin ("EPO"), targeting the treatment of stroke. The twin objectives of the treatment are to stimulate the growth and differentiation of new neurons to replace the brain cells that were lost or damaged by the stroke, and importantly, to direct motor, visual, and cognitive recovery after the acute ischemic stroke. Encouraging clinical results from SCT"s BETAS Phase IIa stroke trial were presented at the International Stroke Conference in February 2009, showing clinically relevant recovery in 12 of 12 patients who received the complete treatment. SCT received clearance from the FDA to proceed with the Phase IIb stroke trial on May 15, 2009. Stem Cell Therapeutics Corp.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009